Reshma Kewalramani

This profile gathers the share dealings of Reshma Kewalramani across 2 companies, led by Vertex Pharmaceuticals INC / MA and Ginkgo Bioworks Holdings, Inc. We count 140 filings; the first trade dates from 8 October 2018 and the latest from 27 February 2026.

Market trades split into 4 purchases (€5.0M) and 75 sales (€72.9M). Taken together, the sales exceed the purchases by €67.9M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 47 share grants and 14 option exercises. Since January 2026: no purchases and 13 sales on the market.

A typical purchase (the median) is worth €1.2M. 4 out of 4 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster.

The latest filing, published on 3 March 2026, reports an open-market sale of €49k in Vertex Pharmaceuticals INC / MA. The last insider purchase was made public on 7 August 2025, 442 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.